uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted October 12, 2013

Metagenics Enzyme Supplement Recalled Due To Drug Risk

On October 11, 2013, Metagenics Canada issued a voluntary recall of digestive enzyme supplement Spectrazyme, due to potential contamination with the prescription antibiotic chloramphenicol.

Because of risks associated with its use, chloramphenicol should only be taken under medical supervision. This antibiotic is associated with an increased risk of a rare but serious, and potentially fatal blood disorder called aplastic anemia; this reaction cannot be predicted and can occur even with small doses. Chloramphenicol can also affect bone marrow, leading to decreased blood cells. It should not be taken by pregnant or lactating women, or those with a known sensitivity to the drug.

Recalled Spectrazyme can be identified by Lot # 0413083. Although this product is imported and sold by Metagenics Canada, it was manufactured by Metagenics Inc. in the U.S., and may be available to U.S. consumers through the company's website or other major online retailers.  

Spectrazyme contains protease, papain, amylase, peptidase, lactase, lipase, cellulase, maltase and invertase and amla fruit (Phyllanthus emblica) and is promoted for digestive support. See's Reviews of Digestive Enzyme Supplements and Lactase Supplements for tests of related products.

See Related Warnings:

Prebiotic and Digestive Enzyme Supplement Recalled Due To Drug Risk

For more about this recall, use the link below.